Mammary Cell News

Mammary Cell News is an online resource covering the latest research into breast cancer and mammary cells.

ERα Dysfunction Caused by ESR1 Mutations and Therapeutic Pressure Promotes Lineage Plasticity in ER+ Breast Cancer

January 16, 2025

[Nature Cancer] Researchers studied the impact of ERα antagonist/degraders against Esr1 mutations expressed in mouse mammary glands.

Targeting the ERK1/2 and p38 MAPK Pathways Attenuates Golgi Tethering Factor Golgin-97 Depletion-Induced Cancer Progression in Breast Cancer

January 16, 2025

[Cell Communication and Signaling] Scientists demonstrated a novel regulatory role of golgin-97 in ERK/MAPK signaling and the tumor microenvironment, possibly providing new insights for anti-breast cancer drug development.

Co-Targeting of Metabolism using Dietary and Pharmacologic Approaches Reduces Breast Cancer Metastatic Burden

January 16, 2025

[NPJ Breast Cancer] Building on previous research that identified metastatic-niche-specific metabolic vulnerabilities, researchers investigated how a ketogenic diet enhances estrogen receptor-positive liver metastatic breast cancer’s response to Fulvestrant treatment.

MicroRNA Dynamics, PTEN/PI3K/AKT Signaling, and Their Relationship to Breast Cancer: Prospects for Pharmaceuticals and Natural Product Application

January 16, 2025

[Breast Cancer Research and Treatment] The authors focus on the understanding of the roles that microRNA and PI3/PTEN/AKT signaling pathways play in regulating breast cancer.

Complex Rearrangements Fuel ER+ and HER2+ Breast Tumors

January 9, 2025

[Nature] Researchers established a meta-cohort of 1,828 breast tumours spanning pre-invasive, primary invasive, and metastatic disease with whole-genome and transcriptome sequencing. They demonstrated that breast tumours fell along a continuum constrained by three genomic archetypes.

A Prospective, Phase II, Neoadjuvant Study Based on Chemotherapy Sensitivity in HR+/HER2- Breast Cancer-FINEST Study

January 7, 2025

[Cancer Communications] This Phase II, single-arm, prospective study aimed to explore appropriate neoadjuvant treatment strategies for HR+/HER2- breast cancer patients.

Yale School of Medicine Receives $1 Million Gift toward Breast Cancer Research

January 3, 2025

[YSM] The Yale School of Medicine (YSM) has received a $1 million gift from Raj and Indra Nooyi. Under the direction of Dr. Mehra Golshan and Dr. Parisa Lotfi, this funding will support research aimed at reducing the toxicity and burden of cancer treatment.

Adjuvant Dose-Dense Chemotherapy in Hormone Receptor–Positive Breast Cancer

January 3, 2025

[Journal of Clinical Oncology] The authors reported 12-year outcomes of the C9741 trial overall, and by the sensitivity to endocrine therapy test index, a biomarker measuring endocrine transcriptional activity, to identify patients most likely to benefit from dose-dense chemotherapy.

Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—The Phase III...

January 3, 2025

[Journal of Clinical Oncology] The MECCA trial demonstrated a significant improvement in progression-free and overall survival with first-line metronomic capecitabine plus aromatase inhibitor (AI) compared with AI alone in patients with hormone receptor-positive+/HER2-negative metastatic breast cancer.

A Novel lncRNA AC112721.1 Promotes the Progression of Triple-Negative Breast Cancer by Directly Binding to THBS1 and Regulating miR-491-5p/C2CD2L Axis

January 2, 2025

[Scientific Reports] The authors identified a novel lncRNA, AC112721.1, that was overexpressed in TNBC and was associated with poor overall survival in TNBC patients. Loss- and gain-of-function experiments revealed that AC112721.1 promoted cell proliferation and migration, suppressed cell apoptosis in vitro and inhibited tumorigenesis in vivo.

NOS Inhibition Sensitizes Metaplastic Breast Cancer to PI3K Inhibition and Taxane Therapy via C-JUN Repression

January 2, 2025

[Nature Communications] Scientists reported that nitric oxide synthase (NOS) blockade potentiated response of human metaplastic breast cancer cell lines and tumors to phosphoinositide 3-kinase (PI3K) inhibitor alpelisib and taxane.

Current and Future Immunotherapy for Breast Cancer

January 2, 2025

[Journal of Hematology & Oncology] The authors provide an update of recent major clinical trials of immunotherapy in breast cancer and discuss future directions in the treatment of breast cancer.

For over a decade, Mammary Cell News has been keeping the global scientific and medical communities informed about the latest research, reviews, and news in the field of mammary tissues. Our editors gather publications on the topic of mammary cell differentiation and characterization, as well as the progression and treatment of breast cancer. We also keep scientists up-to-date on the latest policy changes, job postings, and events.